Evolus(US:EOLS)2022-08-02 19:29Financial Data and Key Metrics Changes - Net revenues for Q2 2022 were $37.2 million, a 42% increase from $26.1 million in Q2 2021, driven by higher volumes and a slightly higher average selling price [34][10] - U.S. sales growth rate was 46%, significantly above the estimated market growth rate [34][11] - Reported gross margin for Q2 was 55.4%, with an adjusted gross margin of 57.4%, expected to improve to 68% to 71% in Q4 2022 due to the end of royalty obligations [35][36] Business Line Data and Key Metrics Changes - The company added nearly 590 new customers in Q2, bringing the total account base to over 8,100, with a reorder rate above 70% [12][9] - Jeuveau achieved a number one or number two toxin share position in practices that adopted the product, indicating strong market penetration [13][15] Market Data and Key Metrics Changes - The aesthetic neurotoxin market continues to show strong demand, with the company expecting to achieve the upper end of its full-year sales guidance of $143 million to $150 million, reflecting a year-over-year growth rate approaching 50% [10][42] - The company is preparing to launch Nuceiva in Europe, targeting Great Britain and Germany, which represent nearly 40% of the European market [22][59] Company Strategy and Development Direction - Evolus aims to become a multi-product aesthetic company, investing in a licensing agreement for 3D printing technology to develop new aesthetic applications [30][29] - The "Switch Your Tox" promotional campaign is designed to increase Jeuveau usage among injectors and patients, providing significant discounts to encourage adoption [21][73] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the resilience of the aesthetic neurotoxin market, citing strong consumer engagement and purchasing patterns despite macroeconomic headwinds [18][19] - The company believes it can grow faster than the overall toxin market, leveraging its unique business model focused on cash pay aesthetics and targeting millennial consumers [20][10] Other Important Information - The company ended Q2 2022 with $84.5 million in cash, down from $106.7 million at the end of Q1, but remains on track for sustainable positive cash flow [40][41] - The company is actively exploring business development opportunities to expand its product portfolio, with a focus on commercial stage assets in aesthetics [60][62] Q&A Session Summary Question: Market opportunity for extra-strength Jeuveau and launch preparation for Nuceiva in Europe - Management indicated high interest in extra-strength Jeuveau, with 86% of customers expressing interest, and discussed modest expectations for Nuceiva's initial sales in Europe [49][51][57] Question: Growth strategies and consumer loyalty program impact - Management confirmed plans to deepen market penetration and expand the customer base, emphasizing the effectiveness of the Evolus program and the new consumer loyalty initiative [64][70][73] Question: Third quarter expectations and business development considerations - Management acknowledged traditional seasonality may return in Q3 due to increased consumer travel, while also clarifying that they are open to considering devices in their business development strategy [76][78] Question: Customer base targets and leveraging recent publications - Management noted a long-term goal of reaching a broader customer base while utilizing recent research on millennials to drive Jeuveau adoption [84][86][88]